Provided herein are thiazolidinedione analogues that are useful for treating non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), diabetes, and other metabolic inflammation-mediated disease and disorders. Further, provided herein are non-invasive methods and systems for assessing a subject's risk of having NASH. Moreover, provided herein are non-invasive methods and systems for evaluating whether a treatment of NASH is effective.

The present invention relates to a method for quantification of amino acids using a cell-free protein synthesis system. Specifically, the present invention relates to a method for quantification of amino acids, comprising: (a) preparing a reaction mixture for cell-free protein synthesis without target amino acids; (b) performing cell-free protein synthesis by mixing an assay sample containing target amino acids with the reaction mixture for cell-free protein synthesis; (c) measuring the signal intensity of the synthesized protein; and (d) calculating the concentration of the target amino acids by comparing the measured signal intensity with the standard concentration curve for each amino acid according to the protein signal produced using a standard sample, a method for providing information for diagnosing an amino acid metabolism-related disease using the same, a method for screening a material for prevention or treatment of an amino acid metabolism-related disease, and a method for screening a transaminase substrate. The method for quantification of amino acids according to the present invention can quantify amino acids in a short time at a low cost, and thus can be useful in various industries.

The present invention relates to a method for quantification of amino acids using a cell-free protein synthesis system. Specifically, the present invention relates to a method for quantification of amino acids, comprising: (a) preparing a reaction mixture for cell-free protein synthesis without target amino acids; (b) performing cell-free protein synthesis by mixing an assay sample containing target amino acids with the reaction mixture for cell-free protein synthesis; (c) measuring the signal intensity of the synthesized protein; and (d) calculating the concentration of the target amino acids by comparing the measured signal intensity with the standard concentration curve for each amino acid according to the protein signal produced using a standard sample, a method for providing information for diagnosing an amino acid metabolism-related disease using the same, a method for screening a material for prevention or treatment of an amino acid metabolism-related disease, and a method for screening a transaminase substrate. The method for quantification of amino acids according to the present invention can quantify amino acids in a short time at a low cost, and thus can be useful in various industries.

Provided is use of immobilized transaminase in preparation of sitagliptin and/or (R)-3-amino-1-morpholine-4-(2,4,5-trifluorophenyl)-1-butanone. The immobilized transaminase comprises resin and a transaminase mutant, the amino acid sequence of the transaminase mutant is as shown in SEQ ID NO: 3 or SEQ ID NO: 7. Also provided is an immobilized transaminase, a transaminase mutant, a preparation method therefor and use thereof. The enzyme activity of the transaminase mutant in the catalysis of a ketoamide substrate is high, and the enzyme activity is still high after the transaminase mutant is prepared into the immobilized transaminase. When the transaminase mutant is used for catalyzing the ketoamide substrate to produce sitagliptin or an intermediate thereof, a screened solvent reaction system is combined, the immobilized transaminase is high in conversion rate and good in stereoselectivity and stability, the repeatability rate is improved, and the operation is simpler, thereby reducing the cost of production, and it is beneficial to industrial production.

An object of the present invention is to provide a blood analysis method and a blood test kit, which are for performing quantitative analysis of components by precisely obtaining a dilution factor. According to the present invention, provided is a blood analysis method including a step of diluting a collected blood sample with a diluent solution; a step of determining a dilution factor by using a normal value of a normal component which is homeostatically present in blood; and a step of analyzing a concentration of a target component in the blood sample, in which the blood analysis method uses a member selected from the group consisting of a first storing instrument for storing a diluent solution, a separation instrument for separating and recovering blood plasma from the blood sample diluted with the diluent solution, a holding instrument for holding the separation instrument, a second storing instrument for storing the recovered blood plasma, and a sealing instrument for keeping the stored blood plasma within the second storing instrument, in which the diluent solution defines an amount of the normal component which is derived from the diluent solution and/or the members and may be contained in the diluent solution, and in which a volume of the blood sample is 50 μL or less, and a dilution factor of a blood plasma component in the blood sample is 14 times or more.

An object of the present invention is to provide a blood analysis method and a blood test kit, which are for performing quantitative analysis of components by precisely obtaining a dilution factor. According to the present invention, provided is a blood analysis method including a step of diluting a collected blood sample with a diluent solution; a step of determining a dilution factor by using a normal value of a normal component which is homeostatically present in blood; and a step of analyzing a concentration of a target component in the blood sample, in which the blood analysis method uses a member selected from the group consisting of a first storing instrument for storing a diluent solution, a separation instrument for separating and recovering blood plasma from the blood sample diluted with the diluent solution, a holding instrument for holding the separation instrument, a second storing instrument for storing the recovered blood plasma, and a sealing instrument for keeping the stored blood plasma within the second storing instrument, in which the diluent solution defines an amount of the normal component which is derived from the diluent solution and/or the members and may be contained in the diluent solution, and in which a volume of the blood sample is 50 μL or less, and a dilution factor of a blood plasma component in the blood sample is 14 times or more.

The embodiments of the present application, belonging to the technical field of medical test and assay, and provide a preservative for an in vitro diagnostic reagent. The preservative includes a combination of a sulfadoxine solution and a dimethoprim solution, wherein a molar ratio of sulfadoxine in the sulfadoxine solution to dimethoprim in the dimethoprim solution is from 0.002 to 1. The present disclosure also provides use of the preservative for the in vitro diagnostic reagent. The technical solutions according to the embodiments of the present disclosure improve stability of the reagent, do not affect reactions of the reagent, and may be extensively applied.

The embodiments of the present application, belonging to the technical field of medical test and assay, and provide a preservative for an in vitro diagnostic reagent. The preservative includes a combination of a sulfadoxine solution and a dimethoprim solution, wherein a molar ratio of sulfadoxine in the sulfadoxine solution to dimethoprim in the dimethoprim solution is from 0.002 to 1. The present disclosure also provides use of the preservative for the in vitro diagnostic reagent. The technical solutions according to the embodiments of the present disclosure improve stability of the reagent, do not affect reactions of the reagent, and may be extensively applied.

The present invention provides systems, devices, and methods for point-of-care and/or distributed testing services. The methods and devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device can be modified to allow for more flexible and robust use with the disclosed methods for a variety of medical, laboratory, and other applications. The systems, devices, and methods of the present invention can allow for effective use of samples by improved sample preparation and analysis.

The present invention provides systems, devices, and methods for point-of-care and/or distributed testing services. The methods and devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device can be modified to allow for more flexible and robust use with the disclosed methods for a variety of medical, laboratory, and other applications. The systems, devices, and methods of the present invention can allow for effective use of samples by improved sample preparation and analysis.